Clorox (NYSE:CLX) Price Target Cut to $127.00 by Analysts at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. has lowered its price target for Clorox from $135.00 to $127.00, indicating a neutral rating with a potential upside of 5.85% from the current stock price.
• Additional analysts have also reduced their price targets, with Barclays setting a target of $112.00 and Morgan Stanley adjusting it to $137.00, reflecting a generally cautious outlook for the stock.
• Clorox's recent earnings report showed a profit of $2.87 per share, exceeding analyst expectations, and the company anticipates earnings between $5.950 and $6.30 per share for FY 2026.

Clorox (NYSE:CLX - Get Free Report) had its price objective reduced by equities research analysts at JPMorgan Chase & Co. from $135.00 to $127.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 5.85% from the company's current price.

Other analysts have also recently issued research reports about the company. Barclays cut their price target on Clorox from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Tuesday, September 30th. Morgan Stanley lowered their price objective on shares of Clorox from $150.00 to $137.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Weiss Ratings reiterated a "hold (c)" rating on shares of Clorox in a research report on Saturday, September 27th. Wells Fargo & Company cut their price target on Clorox from $130.00 to $125.00 and set an "equal weight" rating on the stock in a research report on Thursday, September 25th. Finally, Bank of America decreased their target price on shares of Clorox from $135.00 to $125.00 and set a "neutral" rating for the company in a research note on Wednesday. One research analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Reduce" and a consensus target price of $131.92.

Clorox Price Performance

Clorox stock opened at $119.98 on Friday. Clorox has a 1 year low of $116.53 and a 1 year high of $171.37. The stock has a market cap of $14.67 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 0.98 and a beta of 0.52. The firm has a 50-day moving average of $122.27 and a two-hundred day moving average of $128.94. The company has a debt-to-equity ratio of 5.15, a current ratio of 0.84 and a quick ratio of 0.57.

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating analysts' consensus estimates of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The business had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same period in the previous year, the company posted $1.82 EPS. Clorox's revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. On average, research analysts forecast that Clorox will post 7.15 earnings per share for the current year.

Insider Activity at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the transaction, the chief operating officer owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.57% of the company's stock.

Hedge Funds Weigh In On Clorox

Several institutional investors and hedge funds have recently bought and sold shares of the company. Total Investment Management Inc. acquired a new position in Clorox in the second quarter valued at approximately $25,000. American National Bank & Trust grew its holdings in shares of Clorox by 69.5% in the second quarter. American National Bank & Trust now owns 217 shares of the company's stock valued at $26,000 after purchasing an additional 89 shares in the last quarter. NewSquare Capital LLC increased its position in shares of Clorox by 567.6% during the second quarter. NewSquare Capital LLC now owns 227 shares of the company's stock worth $27,000 after acquiring an additional 193 shares during the period. Darwin Wealth Management LLC purchased a new stake in Clorox during the 2nd quarter worth about $29,000. Finally, Bank & Trust Co purchased a new stake in shares of Clorox during the third quarter worth approximately $30,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.